Hexarelin
$Potent GH secretagogue; Higher endocrine spillover and desensitization risk
Hexarelin, also called examorelin, is a synthetic GH secretagogue in the GHRP family. It is known for strong GH release and potential cardiovascular research interest.
The mechanism is stronger than the wellness evidence. It can trigger hormone changes, but long-term body-composition, recovery, or longevity claims remain separate questions. Know that stronger is not automatically better. Monitor IGF-1, glucose, edema, blood pressure, prolactin/cortisol context, and loss of effect over time.
Classification details
- Hexarelin is a synthetic hexapeptide and potent agonist of the growth hormone secretagogue receptor.
- It is chemically related to older GHRPs and is generally considered more intense and more prone to desensitization than gentler options.
- Hexarelin is a potent synthetic GHS-R agonist in the GH-secretagogue family. It is distinct from ipamorelin because it is less selective and has stronger desensitization and off-target endocrine concerns.
- Direct pituitary stimulation: binds GHS-R receptors to release a large GH pulse, widely considered the most potent GHRP for the sheer height of the spike.
- Somatostatin inhibition: suppresses the body's natural brake on GH release.
- Cardioprotection: uniquely also binds CD36 receptors in the heart and blood vessels, and research shows it can protect heart cells from ischemic damage.
- Tissue repair: like other GHRPs it raises IGF-1, aiding muscle protein synthesis and systemic repair.
- Hormonal bleed: more than ipamorelin, it can nudge ACTH, cortisol, and prolactin in some settings.
- It stimulates GH release via GHS-R and may affect ACTH/cortisol/prolactin more than selective secretagogues. Cardiac research signals exist, but that does not make it a cardioprotective therapy.